July 1, 2022

Accelerated Approval Matters

Accelerated Approval Matters

Accelerated approval drugs have given patients access to care they otherwise would have waited years for. A new study shows that these drugs account for less than 1% of Medicaid spending - yet programs have placed restrictions on these medicines to curb spending. 

We hear from the author of that study, Dr. Kenneth Thorpe, about its findings and alternative solutions to cut costs without compromising patient access to innovative care. 

Plus, hear from Lyme Disease advocate Grace Shults about advocacy and the need for improved testing and care for this chronic condition.


Terry Wilcox, Executive Director, Patients Rising

Dr. Robert Goldberg, “Dr. Bob,” Co-Founder and Vice President of the Center for Medicine in the Public Interest

Kate Pecora, Field Correspondent 


Kenneth Thorpe, PhD., Chair, Partnership to Fight Chronic Disease

Grace Shults, Host, Generation Lyme

Jenny Jones, Patient Correspondent


New Analysis Finds Accelerated Approval Drugs Do Not Drive Medicaid Spending

Deep Inside the Gun Bill: A Break for Prescription Drug Middlemen

Need help?

The successful patient is one who can get what they need when they need it. We all know insurance slows us down, so why not take matters into your own hands? Our Navigator is an online tool that allows you to search a massive network of health-related resources using your zip code so you get local results. Get proactive and become a more successful patient right now at PatientsRisingConcierge.org

Have a question or comment about the show, or want to suggest a show topic or share your story as a patient correspondent?

Drop us a line: podcast@patientsrising.org

The views and opinions expressed herein are those of the guest(s)/ author(s) and do not reflect the official policy or position of Patients Rising.